Adolor Corporation, Exton, Pa., (Nasdaq:ADLR) has announced that
clinical testing will be permitted under an Investigational New Drug
Application (IND) for ADL5747, a novel oral compound that targets the
Delta opioid receptor. Adolor expects to initiate Phase 1 clinical
testing in the first quarter of 2008.
ADL5747 is the second delta compound that will enter clinical
investigation under Adolor's worldwide collaboration with Pfizer
Inc (NYSE:PFE) to develop novel pain compounds. A lead compound,
ADL5859, is in Phase 2 clinical testing in several pain conditions.
About the Delta Receptor Program
The Delta receptor is one of three opioid receptors. Through a
proprietary research platform based on cloned, human opioid receptors,
Adolor has identified a series of novel, orally active Delta agonists
compounds that selectively stimulate the Delta opioid receptor. Delta
compounds may have a number of potential advantages, including an
improved side effect profile, as compared to mu opioid receptor
agonists. On the basis of preclinical evaluation in animal models of
human conditions, one might expect a Delta agonist to show effect in
inflammatory pain, among other pain conditions. In addition, Delta
agonists are thought to modulate other biological processes that may
manifest themselves in disease states or conditions such as
cardioprotection, overactive bladder, and depression.
There are currently no selective Delta agonists approved by the
FDA.
About the Delta Collaboration
Adolor and Pfizer Inc (NYSE:PFE) are collaborating on the worldwide
development and commercialization of two novel Delta opioid agonist
compounds, ADL5859 and ADL5747, for the treatment of pain.
About Adolor Corporation
Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company
specializing in the discovery, development and commercialization of
novel prescription pain management products. Adolor has two lead product
candidates in development: Entereg[R] (alvimopan) for the management of
the gastrointestinal side effects associated with opioid use; and, novel
Delta opioid receptor agonists for a variety of pain indications. Adolor
and GlaxoSmithKline are collaborating in the worldwide development and
commercialization of Entereg in multiple indications. Adolor and Pfizer
are collaborating in the worldwide development and commercialization of
two Delta agonists for pain. Adolor also has a number of discovery
research programs focused on the identification of novel compounds for
the treatment of pain. By applying its knowledge and expertise in pain
management, along with ingenuity, Adolor is seeking to make a positive
difference for patients, caregivers and the medical community.
For more information, visit http://www.adolor.com or call
484/595-1500.
COPYRIGHT 2008 Worldwide
Videotex Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.